Alteration of early dendritic cell activation by cancer cell lines predisposes immunosuppression, which cannot be reversed by TLR4 stimulation

Ying Ying Kong, Martina Fuchsberger, Magdalena Plebanski, Vasso Apostolopoulos

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)


Dendritic cells (DCs) have shown promise for use in cancer vaccine and cancer immunotherapy studies. However, we demonstrate that cancer cell lines can negatively interfere with DC generation in granulocyte-macrophage colony-stimulating factor (GM-CSF)-derived cultures, although cancer cells are able to enhance CD80 cell surface activation marker and cytokine secretion. Furthermore, in the presence of cancer cells, GM-CSF-derived DCs are unable to stimulate T-cells. Additional stimulation with toll-like receptor 4 cannot fully reverse the suppressive effect of cancer cells or supernatant. Hence, it is imperative to understand the immunosuppressive effects of cancer on DCs in order for DC-based cancer immunotherapy to be successful.

Original languageEnglish
Pages (from-to)1101-1111
Number of pages11
JournalActa Biochimica et Biophysica Sinica
Issue number12
Publication statusPublished - 2016


  • Cytokines
  • Dendritic cells
  • Early dendritic cells
  • GM-CSF

Cite this